A new fixed-dose combination therapy pairing obicetrapib with the cholesterol-lowering drug ezetimibe significantly reduced low-density lipoprotein (LDL) cholesterol levels in patients whose cholesterol remained elevated despite statin use, according to research published in The Lancet.
The randomized, double-blind study enrolled 407 participants at 48 U.S. sites for a phase 3 clinical trial. All participants had either established atherosclerotic cardiovascular disease, were at high risk for it or had familial hypercholesterolemia.
After 84 days of treatment, the once-daily oral therapy reduced LDL cholesterol levels by 48.6% compared to the placebo, a greater reduction than seen with either obicetrapib or ezetimibe alone.
Researchers said the therapy may provide a new treatment option for patients who require additional LDL-lowering beyond what statins can provide.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
